Alumis (ALMS) to Release Earnings on Wednesday

Alumis (NASDAQ:ALMS - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, June 18th. Analysts expect the company to announce earnings of ($1.47) per share for the quarter.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($0.35). On average, analysts expect Alumis to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Alumis Price Performance

Alumis stock traded down $0.11 during trading hours on Thursday, hitting $3.18. The stock had a trading volume of 816,895 shares, compared to its average volume of 400,855. Alumis has a one year low of $3.16 and a one year high of $13.53. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $6.15.

Insider Activity

In other Alumis news, Director Alan Colowick bought 16,104 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was acquired at an average price of $6.97 per share, with a total value of $112,244.88. Following the completion of the purchase, the director now directly owns 16,104 shares of the company's stock, valued at approximately $112,244.88. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Martin Babler bought 15,650 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average cost of $6.44 per share, with a total value of $100,786.00. Following the purchase, the chief executive officer now directly owns 106,454 shares of the company's stock, valued at $685,563.76. This trade represents a 17.23% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 397,044 shares of company stock valued at $1,891,895.

Institutional Investors Weigh In On Alumis

Several large investors have recently added to or reduced their stakes in ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Alumis by 64.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after purchasing an additional 4,926 shares during the period. Goldman Sachs Group Inc. grew its stake in Alumis by 24.0% during the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company's stock worth $378,000 after purchasing an additional 11,949 shares during the period. Jane Street Group LLC acquired a new stake in Alumis during the first quarter worth approximately $111,000. Finally, Rhumbline Advisers grew its stake in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after acquiring an additional 2,949 shares during the period.

Analysts Set New Price Targets

Several equities analysts have commented on ALMS shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research report on Thursday, March 20th. Oppenheimer dropped their target price on Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Guggenheim upgraded Alumis to a "buy" rating and set a $18.00 target price for the company in a research report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 target price on shares of Alumis in a research report on Wednesday, April 30th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $22.86.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.